Treatment Of Medical, Psychiatric, and Substance Use Co-morbidities In People Infected With HIV Who Use Drugs Frederick L. Altice (US, Malaysia, Ukraine)

Slides:



Advertisements
Similar presentations
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Advertisements

Turning the tide: Not without prisons! Promoting comprehensive national HIV responses.
Precautions Courtesy of Louis B. Mallory, MBA, REMT-P.
European Guidelines for the HIV Treatment Esteban Martínez Infectious Diseases Unit Hospital Clínic University of Barcelona Barcelona SPAIN.
13 Principles of Effective Addictions Treatment
Specific issues and guidelines for HCV treatment in IDUs Bern d Schulte Centre for Interdisciplinary Addiction Research (CIAR), University Hamburg.
Part A/Module A1/Session 4 Part A: Module A1 Session 4 Comprehensive Care for People Living with HIV/AIDS (PLHA)
The U.S. President’s Emergency Plan for AIDS Relief The Evolving HIV Prevention Strategy for IDUs in PEPFAR Amb. Eric Goosby US Global AIDS Coordinator.
1 HIV, Tuberculosis and Criminal Justice The Perfect Storm Frederick L. Altice, M.D., M.A. Professor of Medicine and Public Health Yale University (USA)
Mortality Among a Tuberculosis Outbreak Los Angeles County, 2007–2013 Brian Baker, MD Amit Chitnis, MD MPH Leslie Henry, BSN RN PHN 48th CTCA Educational.
Combined prevention programs within criminal justice systems – examples from Malaysia A Kamarulzaman, S Kaur, MN Nazar, M Azahari, C Koh, H AlDarraji,
Chapter 8 Depression and Human Immunodeficiency Virus Francine Cournos, MD Karen McKinnon, MA Mark Bradley, MD Copyright © World Psychiatric Association.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
HIV/AIDS and Substance Use Disorders Olivera J. Bogunovic, M.D. State University of New York at Buffalo Alcohol Medical Scholars Program.
HIV Prevention, treatment and care among people who inject drugs Fabienne Hariga, MD, MPH Senior HIV Adviser, UNODC Vienna.
Annabel Baddeley Global TB Programme WHO, Geneva
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
HIV and Behavioral Health: An Update from SAMHSA Elinore F. McCance-Katz, MD, PhD Chief Medical Officer Substance Abuse and Mental Health Services Administration.
HIV and Injection Drug Use
Adult Viral Hepatitis Update Roxanne Ereth, MPH, BS Hepatitis C Program Manager Adult Viral Hepatitis Prevention Coordinator.
T UBERCULOSIS. P HYSICAL ILLNESS Physical illness among IDUs is more common as compared to the general population A Study from Chennai conducted in 2005.
Meeting the health needs of older drug users Dr Muriel Simmonte NHS Lothian Primary Care Facilitator Team/East Lothian Locality Drug Clinic.
Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.
RCGP training online: new training in short bites Danny Morris, Expert Lead RCGP Hepatitis B and C Part 1.
C OMORBIDITY. W HAT IS COMORBIDITY ? When two disorders or illnesses occur concurrently in the same person, they are called comorbid Drug abuse and other.
Recommendations on the Management of Opioid Overdose Ruth Birgin.
Psychopharmacology – A brief introduction. Objectives Review general categories of psychiatric disorders Review general categories of psychiatric disorders.
1 First Clinic Visit for Patients with HIV Infection HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Responding to Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Good Prescribing to support Criminal Justice Interventions
Co-occurring Challenges: Leveraging ADAP and ACA to Address Hepatitis C and Substance Use Disorders Daniel Raymond Policy Director Harm Reduction Coalition.
Opioid addiction treatment: Challenges (and opportunities) for community practice Marc Fishman MD.
Tuberculosis What is tuberculosis?.
Emotional and Psychiatric Barriers to Addressing HCV Joan E. Zweben, Ph.D. Executive Director: 14 th Street Clinic and East Bay Community Recovery Project.
Office of Overseas Programming & Training Support (OPATS) Treatment Adherence HIV Care, Support, and Treatment.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2012.
1 Care for Injection Drug Users (IDUs) with HIV HAIVN Havard Medical School AIDS Initiative in Vietnam.
Increased case detection in infants and children Robert Gie Childhood TB Subgroup.
1 Kennedy Roberts Senior Medical Officer and Clinical Lead North Cluster Glasgow Addiction Services Community Addiction Teams What are the challenges for.
1 HIV and Injection Drug Use HAIVN Harvard Medical School AIDS Initiative in Vietnam.
HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Introduction to NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Office of the Director Jonathan Mermin, MD, MPH National.
Pennsylvania: The State of HCV 2015
Treatment and scale up access TV, ART OST treatment for people who use drug sin SEA Ekta.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Injection Drug Use and Hepatitis C What Can We Do About It? Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse.
Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.
AIDS 2014 Workshop on increasing access to TB services as part of integrated care for people who inject drugs Integrating TB services.
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Principles of Effective Drug Addiction Treatment Health 10 The Truth About Drugs Ms. Meade.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
1 Community-Based Research with Substance Dependent Offenders Randall Brown MD, PhD Health Improvement & Research Partnerships Forum Madison, WI 9/15/2011.
Lessons Learned and Novel Investigation Techniques in Response to a Large Community Outbreak of HIV-1 infection Philip J. Peters MD HIV Testing and Biomedical.
Mary Lou Leary Deputy Director for State, Local, and Tribal Affairs Office of National Drug Control Policy A Drug Policy for the 21 st Century A Drug Policy.
#AIDS2016 HOW TO LAUNCH PROGRAMMES FOR PEOPLE WHO USE SUBSTANCES AND ARE AFFECTED BY HIV ACROSS MORE GENERALIZED HIV EPIDEMIC SETTINGS.
Deadly trio: mental health – HIV - drugs
Tuberculosis in children
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Optimizing Care for PWIDs
Cascade of care for people who use drugs - opportunities for integration and scale up of harm reduction services and other evidence based interventions.
Drugs and Neuron Communication
Medication-Assisted Therapy at Coleman Profession Services
Medication Assisted Treatment
Information for Network Providers
More Than Treatment.
HCV Screening.
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
No conflicts of interest
Presentation transcript:

Treatment Of Medical, Psychiatric, and Substance Use Co-morbidities In People Infected With HIV Who Use Drugs Frederick L. Altice (US, Malaysia, Ukraine) Adeeba Kamarulzaman (Malaysia) Vincent Soriano (Spain) Mauro Schechter (Brazil) Gerald Friedland (US, South Africa)

HIV-infected drug users have increased medical and psychiatric co-morbidities HIV and Drug Use Mental Illness (40-60%) Polysubstance Drug Use TB Bacterial Infections Bacterial Infections Chronic Hepatitis C Virus (70-90%) Opportunistic Infections Chronic Hepatitis B Virus ART

Emerging Co-Morbidity Among HIV-infected Persons that Use Drugs

Medication-Assisted Treatments for Treating Substance Use Disorders Work Opioid dependence (methadone, buprenorphine, depot naltrexone) – Sufficient dosing – Requires management of medication interactions – Integration of services – Opportunities to retain patients in care and optimize adherence to cART – Reduces injecting, but not sexual risk behaviors Alcohol dependence (depot naltrexone, acamprosate)

Antiretroviral Medications Work in Drug Users, Yet They Are Seldom Prescribed Outcomes are improved if treatment is optimized – Stabilization through prescription of medication- assisted therapies (methadone, buprenorphine) – Supervised therapy (e.g. DAART) – Adherence and retention support strategies – Effective management of mental illness – Comprehensive, interdisciplinary management preferably through integration of health services – Careful management of pharmacokinetic drug interactions

HIV and Tuberculosis Among People Who Use Drugs TB Exposure among drug users is high; reactivation of latent disease is 9% per year Diagnosis is often complicated – Atypical chest radiographs; low (50%) sputum yield Adherence to TB and cART may be simultaneously optimized (MAT, DOT, adherence support) Medication interactions are common, but manageable – Rifampicin reduces levels of MAT and some antiretroviral medications (Rifabutin)

HIV and Viral Hepatitis Among People Who Use Drugs HCV infection is extremely common – Chronic HCV is emerging as the leading cause of ESLD and death among HIV+ drug users receiving cART – Treatment (PEG+RBV) is effective & expensive – more effective therapies forthcoming, but untested in HIV+s – Current therapies do not interact with MAT, but HCV treatment is optimized when in methadone treatment Chronic HBV infection is endemic in some regions – When HBV treatment is indicated, use simultaneous treatment for HIV using 2 effective HBV agents

Mass Incarceration of HIV+ Drug Users is Hazardous for Individual and Public Health Criminal justice settings, if properly organized, can be effective sites for the diagnosis and treatment of HIV and other co-morbid conditions – Buprenorphine or methadone treatment – Screening, isolation and treatment of TB – Screening and treatment of mental illness, viral hepatitis and STDs Requires effective transitional programs to the community that do not interrupt care

Overview of Clinical Management Review of commonly ingested drugs, their effect on clinical status and impact on HIV treatment & prevention Discussion of available MAT for managing dependence on opioids, alcohol and nicotine dependence Synthesis of infectious and non-infectious complications of drug use in HIV-infected persons Exhaustive review of pharmacokinetic drug interactions between MAT, psychotropic, antibacterial and antiretroviral medications Systematic review of interventions that optimize adherence in drug users, especially those with HIV

Dima’s Voice from Mykolaiv Co-morbid conditions include HIV, opioid dependence, TB (MDR), HCV, bacterial pneumonia Course complicated by opioid withdrawal, fragmentation of care, loss of driver’s license after getting methadone (registration), artificial ceiling for methadone dosing, forced withdrawal from methadone upon hospitalization, and lack of prescription of cART despite clinical need Has survived despite these obstacles, mostly from shear will My doctors are afraid to raise my methadone dose because they tell me I take too many pills already and that it will hurt my liver. I want to take the HIV cocktail that other guys get, but I’m told that I have to wait because the HIV medications will make me sick, be too much for my liver and eat up my methadone like my other TB medications did. The only reason I’m not in the cemetery like all of my friends is that I’m tough like the steel I weld.